Vanguard Group Inc Immunity Bio, Inc. Transaction History
Vanguard Group Inc
- $6.44 Trillion
- Q3 2025
A detailed history of Vanguard Group Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 27,655,205 shares of IBRX stock, worth $57.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,655,205
Previous 21,817,307
26.76%
Holding current value
$57.5 Million
Previous $57.6 Million
18.12%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding IBRX
# of Institutions
296Shares Held
137MCall Options Held
2.59MPut Options Held
3.35M-
Jane Street Group, LLC New York, NY12.8MShares$26.7 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$23.8 Million0.0% of portfolio
-
State Street Corp Boston, MA11.3MShares$23.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.89MShares$14.3 Million0.0% of portfolio
-
Heights Capital Management, Inc San Francisco, CA6.57MShares$13.7 Million4.43% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $833M
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...